NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $1.40 +0.01 (+0.72%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Senti Biosciences Stock (NASDAQ:SNTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Senti Biosciences alerts:Sign Up Key Stats Today's Range$1.38▼$1.4250-Day Range$1.30▼$2.3552-Week Range$1.26▼$16.94Volume20,775 shsAverage Volume169,231 shsMarket Capitalization$36.62 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders. Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities. Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.AI Generated. May Contain Errors. Read More Senti Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 350th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialSenti Biosciences has a consensus price target of $8.50, representing about 507.1% upside from its current price of $1.40.Amount of Analyst CoverageSenti Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Senti Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.02% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.02% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.45 News SentimentSenti Biosciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 2 articles on an average week.Search Interest1 people have searched for SNTI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of Senti Biosciences is held by insiders.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNTI Stock News HeadlinesSenti Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSenti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."September 17 at 2:00 AM | Brownstone Research (Ad)Senti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor SegmentAugust 12, 2025 | quiverquant.comQSenti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid LeukemiaAugust 12, 2025 | globenewswire.comSenti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...August 8, 2025 | finanznachrichten.deSenti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025August 7, 2025 | globenewswire.comSenti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid LeukemiaAugust 5, 2025 | globenewswire.comSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $3.51 at the beginning of 2025. Since then, SNTI shares have decreased by 60.1% and is now trading at $1.40. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. The business earned $0.50 million during the quarter, compared to the consensus estimate of $1.30 million. When did Senti Biosciences' stock split? Shares of Senti Biosciences reverse split before market open on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Senti Biosciences' major shareholders? Senti Biosciences' top institutional shareholders include Armistice Capital LLC (3.41%) and Geode Capital Management LLC (0.56%). View institutional ownership trends. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/07/2025Today9/17/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for Senti Biosciences$8.50 High Price Target$12.00 Low Price Target$5.00 Potential Upside/Downside+515.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-223.98% Return on Assets-76.02% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$2.56 million Price / Sales14.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.26Miscellaneous Outstanding Shares26,160,000Free Float25,344,000Market Cap$36.13 million OptionableNot Optionable Beta2.06 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SNTI) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.